How Semax Works in Research Models
Semax is a synthetic heptapeptide (MEHFPGP) derived from the ACTH(4-7) sequence with a Pro-Gly-Pro C-terminal extension. Researchers have studied it primarily for its BDNF and neurotrophin signaling effects, neuroprotection in ischemia models, and cognitive performance endpoints in rodent paradigms. Published research documents Semax activating neurotrophic gene expression, reducing neuronal apoptosis in ischemic conditions, and modulating the melanocortin system through its ACTH-derived sequence.
Mechanism Steps in Research Models
How researchers have characterized Semax activity in published preclinical studies.
Melanocortin Receptor Activation
Semax activates melanocortin receptors including MC4R through its ACTH(4-7) sequence. Published research has characterized this receptor interaction as initiating downstream cAMP signaling and neuroprotective gene expression changes in neural cell culture systems.
BDNF and Neurotrophin Upregulation
Research has documented Semax increasing BDNF mRNA and protein expression in rodent brain regions including hippocampus and cortex. Published gene expression studies have also characterized upregulation of NGFR and other neurotrophin-related genes, establishing a neurotrophin-based mechanism for cognitive and neuroprotective effects observed in animal models.
Neuroprotection in Ischemia Models
Published ischemia research has documented Semax activating HIF-1alpha pathway genes, reducing neuronal apoptosis as measured by TUNEL assay, and decreasing infarct volume in rodent stroke models. Researchers have characterized these effects as downstream of both melanocortin receptor activation and BDNF upregulation.
Cognitive Function Modulation
Rodent behavioral paradigms including Morris water maze and passive avoidance testing have documented improved learning and memory performance in Semax-treated groups. Published research has correlated these behavioral outcomes with measured increases in hippocampal BDNF expression and synaptic plasticity markers.
Research Observations
Key findings documented in published preclinical studies.
Ischemia and Stroke Models
Published rodent ischemia studies have documented Semax reducing infarct volume, decreasing apoptotic cell death, and improving neurological deficit scores relative to vehicle controls in middle cerebral artery occlusion paradigms.
BDNF and Gene Expression Studies
Research using RT-PCR and immunohistochemistry has documented Semax increasing BDNF expression in hippocampus and cortex of rodent subjects, with published microarray data characterizing broader neurotrophin-related gene expression changes.
Cognitive Behavioral Research
Rodent cognition studies have documented improved performance in spatial memory and avoidance learning tasks in Semax-treated groups, with published data from multiple behavioral paradigm types supporting cognitive enhancement endpoints.
Melanocortin System Research
Cell culture and animal studies have documented Semax activating melanocortin receptors with downstream effects on dopaminergic and serotonergic system parameters, contributing to published data on mood and behavior endpoints in rodent models.
Signaling Summary
In research models, Semax activates melanocortin receptors through its ACTH-derived sequence and stimulates neurotrophin gene expression, particularly BDNF and its receptor TrkB. Researchers have documented HIF-1alpha pathway activation in ischemic models, which contributes to neuroprotective outcomes through anti-apoptotic and angiogenic signaling. Published cognitive research in rodent paradigms has characterized improvements in learning and memory endpoints correlated with measured increases in BDNF expression.
Research Connections
Frequently Asked Questions
Source Research-Grade Semax
Spartan Peptides supplies research-grade Semax at least 98% HPLC-verified purity with Certificate of Analysis. Domestic US supply, same-day dispatch before 2 PM. For in vitro research use only.
For in vitro research use only. Not for human consumption.